<DOC>
	<DOCNO>NCT02970942</DOCNO>
	<brief_summary>Investigation efficacy safety three dose level subcutaneous semaglutide daily versus placebo subject non-alcoholic steatohepatitis</brief_summary>
	<brief_title>Investigation Efficacy Safety Three Dose Levels Subcutaneous Semaglutide Once Daily Versus Placebo Subjects With Non-alcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Informed consent obtain trialrelated activities.Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female , age 1875 year ( inclusive ) ( Japan : male female age 2075 year ( inclusive ) ) time sign informed consent Local histological diagnosis NASH follow histological confirmation NASH base central pathologist evaluation liver biopsy obtain 21 week screen A histological NAS equal 4 score 1 subcomponent score base central pathologist evaluation NASH fibrosis stage 2 3 accord NASH CRN fibrosis stag system base central pathologist evaluation Known suspect abuse alcohol ( 20 g/day woman 30 g/day men ) , alcohol dependence* narcotic . ( * = assess Alcohol Use Disorders Identification Test ( AUDIT questionnaire ) ) Diagnosis type 1 diabetes accord medical record HbA1c 9 % screen History presence pancreatitis ( acute chronic ) Calcitonin equal 50 ng/L screen Family personal history multiple endocrine neoplasia type 2 medullary thyroid carcinoma . Family define first degree relative Body Mass Index ( BMI ) equal 25.0 equal 45.0 kg/m^2 screen visit Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>